Press Releases Year None2021202020192018201720162015201420132012 Sep 19 ESMO Late-breaking Data Show Libtayo® (cemiplimab) and Chemotherapy First-line Treatment Combination Significantly Improved Overall Survival in Patients with Advanced NSCLC Sep 14 Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail Sep 8 Regeneron Announces Investor Conference Presentations Aug 30 Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months Aug 24 Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration Aug 20 UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection Aug 5 Regeneron Reports Second Quarter 2021 Financial and Operating Results Aug 5 Phase 3 Trial of Libtayo® (cemiplimab-rwlc) Combined with Chemotherapy Stopped Early Due to Significant Improvement in Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer Aug 4 New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection Aug 3 Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page »